Skip to main content

Table 2 Multimorbidity prevalence according to disease group by country and gender among people aged 50 and over

From: Trends of multimorbidity in 15 European countries: a population-based study in community-dwelling adults aged 50 and over

  Years CM 95% CI RE 95% CI MS 95% CI ND 95% CI CA 95% CI
AAPC Lower Upper AAPC Lower Upper AAPC Lower Upper AAPC Lower Upper AAPC Lower Upper
Men
 Austria 2004–2017 0.6a 0.0 1.2 3.8a 1.7 5.9 1.3 −2.4 5.2 6.5 −5.0 19.4 0.2 −5.9 6.7
 Belgium 2004–2017 −2.0 −0.9 0.5 2.0a 0.8 3.2 3.7a 2.0 5.5 5.1 −5.4 16.8 −0.3 −4.6 4.2
 Czech Republic 2007–2017 0.6 −0.1 1.3 1.1 −2.7 5.1 6.3a 1.6 11.3 3.7 −8.4 17.5 −0.6 −4.5 3.6
 Denmark 2004–2017 0.6 −0.4 1.5 1.1 −0.9 3.2 −0.5 −1.3 0.4 2.1 −9.5 15.0 −4.6 −11.3 2.5
 Estonia 2011–2017 −1.7 −3.8 0.4 −6.8 −20.4 9.1 − 2.9 −15.1 11.1 7.1a 2.3 12.1 −4.4 − 18.0 11.4
 France 2004–2017 −0.5 −1.2 0.2 0.6 −2.2 3.5 2.3a 0.8 3.8 0.1 −8.9 10.1 −0.7 −3.0 1.8
 Germany 2004–2017 0.9a 0.1 1.6 4.1a 0.7 7.7 8.8a 6.0 11.7 0.7 −8.7 11.1 2.0 −2.9 7.1
 Netherlands 2004–2017 0.5 −1.5 2.5 4.1 −1.0 9.5 5.0 −6.7 18.1 1.0 −16.6 22.4 0.9 −10.9 14.4
 Italy 2004–2017 −0.3 −1.0 0.3 −5.0a −7.4 −2.4 − 5.4a −9.1 − 1.6 6.2 −2.0 15.1 − 1.0 −5.1 3.3
 Poland 2007–2017 0.4 −0.5 1.2 1.3 −0.5 3.2 0.1 − 1.9 2.1 −2.5 −11 6.9 4.7 −1.4 11.2
 Portugal 2011–2017 −1.4a −2.3 −0.6 16.0a 12 20.2 −10.4a −17.9 −2.2 −9.2 −27.7 14.0 −6.1 − 16.9 6.1
 Slovenia 2011–2017 0.0 −0.1 0.2 −1.7 − 12.9 11.0 5.0 −6.1 17.4 17.1a 5.7 29.6 −3.0 −15.6 11.4
 Spain 2004–2017 1.0a 0.3 1.6 −1.1 −3.7 1.7 −1.7 −4.2 0.9 6.8 −2.3 16.8 1.0 −4.8 7.2
 Sweden 2004–2017 −0.4 −1.0 0.2 2.7a 1.4 3.9 5.3a 1.1 9.7 1.5 −9.2 13.4 −4.2 −11.5 3.7
 Switzerland 2004–2017 −0.1 −0.9 0.8 2.3a 0.5 4.1 6.9a 4.2 9.7 3.5 −11.1 20.4 −2.7 −7.4 2.2
Women
 Austria 2004–2017 0.6a 0.0 1.2 3.5a 1.4 5.6 1.2 −2.5 5.1 6 −2.8 15.6 0.1 −6.1 6.7
 Belgium 2004–2017 −0.2 − 0.8 0.5 1.7a 0.6 2.8 3.5a 1.9 5.2 4.6 −3.2 13.1 −0.5 −4.8 4.1
 Czech Republic 2007–2017 0.5 −0.1 1.1 0.8 −2.9 4.6 6.0a 1.4 10.9 4.2 −5.1 14.5 −0.7 −4.8 3.6
 Denmark 2004–2017 0.5 −0.4 1.4 0.8 −1.1 2.8 −0.5 − 1.3 0.3 1.6 −7.4 11.4 −4.7 −11.3 2.3
 Estonia 2011–2017 −1.6 −3.4 0.2 −7.0 −20.2 8.5 −3.0 −14.6 10.2 7.0a 1.0 13.3 −4.7 −18.5 11.6
 France 2004–2017 − 0.5 −1.1 0.1 0.3 −2.4 3.1 2.2a 0.8 3.6 −0.3 −6.6 6.5 −0.8 −3.2 1.7
 Germany 2004–2017 0.8a 0.1 1.5 3.8a 0.4 7.3 8.5a 5.8 11.3 0.3 −6.6 7.8 1.8 −3.0 7.0
 Netherlands 2004–2017 0.4 −1.4 2.2 3.7 −1.3 9.0 4.9 −6.5 17.7 −0.4 −12.9 14.0 0.9 −10.9 14.1
 Italy 2004–2017 −0.3 − 0.9 0.3 − 5.2a − 7.7 −2.7 − 5.4a −9.0 −1.6 5.7a 0.0 11.7 −1.1 − 5.1 3.1
 Poland 2007–2017 0.3 − 0.6 1.2 1.0 −0.8 2.8 −0.1 −1.9 1.8 −1.9 −7.2 3.6 4.6 −1.5 11
 Portugal 2011–2017 −1.3a −2.2 − 0.4 15.8a 12.1 19.6 −10.4a −18 −2.0 − 9.0 − 28 15.2 −6.3 − 16.7 5.4
 Slovenia 2011–2017 0.1 −0.2 0.4 −1.8 −12.9 10.6 4.6 −6.4 17.0 17.1a 3.8 32.0 −3.2 −15.7 11.1
 Spain 2004–2017 0.9a 0.4 1.4 −1.4 − 4.0 1.3 −1.7 − 4.1 0.7 6.3a 0.0 13.0 0.9 −5.0 7.1
 Sweden 2004–2017 − 0.4 −1.0 0.2 2.3a 1.1 3.5 5.1a 1.0 9.4 1.1 −6.8 9.7 −4.3 −11.5 3.5
 Switzerland 2004–2017 −0.1 −0.8 0.7 2.0a 0.2 3.7 6.7a 4.0 9.5 3.1 −8.8 16.6 −2.8 −7.6 2.2
  1. aStatistically significant (p < 0.05); CM Cardiometabolic diseases, RE Respiratory diseases, MS Musculoskeletal diseases, ND Neurodegenerative diseases, CA Cancer